Hearing on Biomedical Research – Keeping America’s Edge in Innovation
Treatment Action Group (TAG) is issuing an urgent call to protect the integrity of biomedical research and public health.
Treatment Action Group (TAG) is issuing an urgent call to protect the integrity of biomedical research and public health.
A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).
This policy brief describes the crucial role NIH plays in supporting research on new products to prevent, diagnose, and cure TB. This research is especially important at a time when new forms of drug resistance are emerging globally, and rates of TB are rising in the U.S. With continued and increased funding, NIH can protect Americans from the growing threat of TB at home and abroad.
Research into curing HIV infection is ever-changing as new discoveries are made and scientists report additional rare — but informative — cases of individuals likely cured of HIV.
Treatment Action Group (TAG) congratulates Malta and Barbados, co-facilitators, and all United Nations (UN) Member States participating in the High-Level Meeting on Antimicrobial Resistance (AMR) upon the publication of the final draft of the Political Declaration.
HIV has evolved multiple mechanisms to evade inhibition by antibodies, which are Y-shaped immune system proteins that normally play a key role in fending off or controlling infections.
On Thursday, April 13, Treatment Action Group (TAG) presented this webinar about important developments in TB vaccine research.
Webinar on March 22 that will provide an update on new research into cases in which the HIV reservoir generates detectable viral load that cannot be suppressed by antiretroviral therapy.
On Tuesday, March 14 at 8:00 am ET, join Treatment Action Group (TAG) and Dr. Jennifer Furin for an overview of key results and breakdown of how they fit into the larger TB policy and research landscapes.
On September 20, please join Treatment Action Group, Dr. Shelly Karuna, and Dr. Karine Dubé for a webinar on the next generation of bnAbs trial design and ethics related to ATIs in HIV vaccine and cure research.